Fosphenytoin vs Oxcarbazepine (Trileptal)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Fosphenytoin

Marketed by Pfizer

Approved in Epilepsysmall molecule
Partial signal

NCT01960075 · Phase 3 · completed

This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.

No aligned efficacy figure on record for this race.

Oxcarbazepine (Trileptal)

Marketed by Novartis

Approved in Epilepsysmall molecule
Weak signal

NCT00050934 · Phase 3 · completed

The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.

Reported efficacy

change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)

Result source: NCT00050934

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFosphenytoinOxcarbazepine (Trileptal)
Seizure frequency, % change—Not posted · NCT00908453—Not posted · NCT00050934
50% responder rate—Not posted · NCT00908453—Not posted · NCT00050934
Seizure freedom—Not posted · NCT00908453—Not posted · NCT00050934

Seizure frequency, % change

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

50% responder rate

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934

Seizure freedom

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Trileptal)
—Not posted · NCT00050934
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Oxcarbazepine (Trileptal)
Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. NCT00050934 · Phase 3 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fosphenytoin: 3 of 4 rows · Oxcarbazepine (Trileptal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFosphenytoinOxcarbazepine (Trileptal)
Dropout rate
38.2%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
14.6%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
12.5%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
—Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
—Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
—
NCT00900237 · Phase 1 · registry result, not featured evidence
—450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
—
NCT01678976 · Phase 1 · registry result, not featured evidence
Serious AEs
0%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
22.2%400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
2.1%a
NCT00975715 · Phase 2/3 · combination
show 5 more results
0%Group 1 (Inducers) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
0%Group 2 (Neutral [Control]) (FAS)
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
0%
NCT00900237 · Phase 1 · registry result, not featured evidence
0%450 mg Bid
NCT01679002 · Phase 1 · registry result, not featured evidence
0%
NCT01678976 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
400mg
respiratory failure 6.7%
acute respiratory failure 4.4%
bradycardia 4.4%
NCT01458522 · Phase 2 · registry result, not featured evidence
a
somnolence 42.6% (placebo 9.8%)
nasopharyngitis 10.6% (placebo 17.6%)
vomiting 10.6% (placebo 5.9%)
NCT00975715 · Phase 2/3 · combination
show 5 more results
somnolence 75%
dizziness 56.3%
headache 50%
NCT03695094 · Phase 1 · registry result, not featured evidence · combination
somnolence 80%
dizziness 66.7%
headache 60%
NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy
headache 100%
dizziness 85.7%
back pain 71.4%
NCT00900237 · Phase 1 · registry result, not featured evidence
450 mg Bid
dizziness 54.5%
somnolence 54.5%
frontal headache 18.2%
NCT01679002 · Phase 1 · registry result, not featured evidence
dizziness 23.1%
headache 23.1%
nodule subcutaneous 15.4%
NCT01678976 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fosphenytoin

Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted
Seizure-free 54.3% (n=35) vs 62.9% (n=35) fPHT @ 0.14wk400mg
event count · % of participants
NCT01458522 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
Seizure Burden -0.58 vs -0.54 fPHT per hour @ 0.14wk400mg
absolute change · per hour
NCT01458522 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Oxcarbazepine (Trileptal)'s landscape